Latigo Biotherapeutics(NASDAQ) LTGO

Market Cap$928.19MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)-23%
5 YearN/A
1 YearN/A
1 Month-38%
$14.77
+5.46%
+0.76Today
After hours$14.74-$0.03 (-0.20%)
Latigo Biotherapeutics last closing stock price
MetricPriceDate
Last closeUSD 14.002026-10-14
Latigo Biotherapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-9.79%USD 15.522026-10-07
1 month-38.16%USD 22.642026-09-14
Since inception-23.29%USD 18.252026-08-07

Latigo Biotherapeutics Financials at a Glance

Market Cap

$928.19MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$95.54

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-0.16 (Low)

Price

$14.77

Volume

242,898

Open

$14.09

Previous Close

$14.76

Daily Range

$13.50 - $14.90

52-Week Range

$13.50 - $25.93

Estimated Earnings Date

Sep 2, 2026

LTGO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Latigo Biotherapeutics

Latigo Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative non-opioid pain medicines. The company aims to provide effective pain relief solutions without the risk of addiction, addressing a significant need in the healthcare sector.

Products and Services
  • Molecule: LTG-001, targeting rapid pain relief
  • Molecule: LTG-32, designed for effective pain management
  • Molecule: LTG-001 IV, offering intravenous pain relief options
Growth Outlook
  • Market demand for non-opioid pain solutions is increasing
  • Strong pipeline of innovative products in development
  • Potential for strategic partnerships to enhance market reach
Financial Highlights
  • Market capitalization of approximately $978 million
  • Stock price range between $15.67 and $25.93 over the past year
  • Average trading volume of 394,256 shares
Latigo Biotherapeutics Inc. is positioned in the healthcare sector, specifically within the medical pharmaceuticals industry. The company is headquartered in Thousand Oaks, California, and employs a dedicated team of 66 professionals. With a focus on non-opioid pain management, Latigo is addressing a critical issue in pain treatment, which has garnered significant attention in recent years. The company's innovative product pipeline and commitment to research and development may provide substantial growth opportunities in the evolving biopharmaceutical landscape.
AI Generated • Oct 6, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

66

CEO

Nima M. Farzan, MBA

Website

www.latigobio.com

Headquarters

Thousand Oak, CA 91320, US

LTGO Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$928.19MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

66.30M

Volume

242.90K

Avg. Volume

369.62K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Latigo Biotherapeutics Performance Analysis

Latigo Biotherapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Latigo Biotherapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD -0.97N/A
20252025-12-31USD -1.7378.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$0.05

N/A

Gross Margin

N/A

N/A

Market Cap

$928.19MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

66

N/A

Net Income

-$25.80

N/A

EBITDA

-$25.76

N/A

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$86.45

N/A

Total Debt

$31.25

N/A

Accounts Receivable

N/A

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.65

N/A

Short Term Debt

$30.60

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-$21.39

N/A

Operating Cash Flow

-$21.28

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
COLLCollegium Pharmaceutical, Inc.
$23.18+2.98%
PCRXPacira BioSciences, Inc.
$36.33-0.19%
SCLXScilex Holding Company
$2.82-1.05%

Trending Stocks

Symbol / CompanyPricePrice Chg
CCCCCC Intelligent Solutions
$7.63-0.13%
INTCIntel
$95.37-2.80%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$107.35-2.89%
CRWVCoreWeave
$69.69+5.94%

Questions About LTGO

What is the current price of Latigo Biotherapeutics?

Latigo Biotherapeutics is trading at $14.76 per share.

What is the 52-week range for Latigo Biotherapeutics?

Over the past 52 weeks, Latigo Biotherapeutics has traded between $13.50 and $25.93.

How much debt does Latigo Biotherapeutics have?

As of the most recent reporting period, Latigo Biotherapeutics reported total debt of $31.25M.

How much cash does Latigo Biotherapeutics have on hand?

Latigo Biotherapeutics reported $55.20M in cash and cash equivalents in its most recent financial results.

What is Latigo Biotherapeutics’s dividend yield?

Latigo Biotherapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services